Ligand Pharmaceuticals Statistics Share Statistics Ligand Pharmaceuticals has 19.6M
shares outstanding. The number of shares has increased by 5.61%
in one year.
Shares Outstanding 19.6M Shares Change (YoY) 5.61% Shares Change (QoQ) 0.2% Owned by Institutions (%) 97.31% Shares Floating 19.09M Failed to Deliver (FTD) Shares 41 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 1.19M, so 6.13% of the outstanding
shares have been sold short.
Short Interest 1.19M Short % of Shares Out 6.13% Short % of Float 7.41% Short Ratio (days to cover) 2.71
Valuation Ratios The PE ratio is -486.05 and the forward
PE ratio is 22.34.
Ligand Pharmaceuticals's PEG ratio is
4.53.
PE Ratio -486.05 Forward PE 22.34 PS Ratio 11.73 Forward PS 13.3 PB Ratio 2.36 P/FCF Ratio 20.58 PEG Ratio 4.53
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Ligand Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.93,
with a Debt / Equity ratio of 0.01.
Current Ratio 8.93 Quick Ratio 8.55 Debt / Equity 0.01 Debt / EBITDA 0.17 Debt / FCF 0.07 Interest Coverage -7.44
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $2.46M Profits Per Employee $-59.29K Employee Count 68 Asset Turnover 0.18 Inventory Turnover 0.78
Taxes Income Tax 6.55M Effective Tax Rate 260.13%
Stock Price Statistics The stock price has increased by 64.87% in the
last 52 weeks. The beta is 0.84, so Ligand Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.84 52-Week Price Change 64.87% 50-Day Moving Average 139.94 200-Day Moving Average 118.42 Relative Strength Index (RSI) 75.21 Average Volume (20 Days) 212,417
Income Statement In the last 12 months, Ligand Pharmaceuticals had revenue of 167.13M
and earned -4.03M
in profits. Earnings per share was -0.22.
Revenue 167.13M Gross Profit 156.06M Operating Income -22.61M Net Income -4.03M EBITDA 40.79M EBIT 5.55M Earnings Per Share (EPS) -0.22
Full Income Statement Balance Sheet The company has 72.31M in cash and 7.11M in
debt, giving a net cash position of 65.2M.
Cash & Cash Equivalents 72.31M Total Debt 7.11M Net Cash 65.2M Retained Earnings 498.98M Total Assets 948.6M Working Capital 288.21M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 97.05M
and capital expenditures -1.82M, giving a free cash flow of 95.23M.
Operating Cash Flow 97.05M Capital Expenditures -1.82M Free Cash Flow 95.23M FCF Per Share 5.21
Full Cash Flow Statement Margins Gross margin is 93.37%, with operating and profit margins of -13.53% and -2.41%.
Gross Margin 93.37% Operating Margin -13.53% Pretax Margin 1.51% Profit Margin -2.41% EBITDA Margin 24.41% EBIT Margin -13.53% FCF Margin 56.98%
Dividends & Yields LGND does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LGND is $180,
which is 7.9% higher than the current price. The consensus rating is "Buy".
Price Target $180 Price Target Difference 7.9% Analyst Consensus Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 2, 2022. It was a
forward
split with a ratio of 1603:1000.
Last Split Date Nov 2, 2022 Split Type forward Split Ratio 1603:1000
Scores Altman Z-Score 14.74 Piotroski F-Score 4
